ReviewCurrent treatment options in oncology2022
Constipation in Cancer Patients - an Update of Clinical Evidence.
Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Experiences and coping strategies related to constipation among individuals with cancer: a qualitative study.BMC palliative care · 2026Article
- Prevalence of opioid-induced constipation in the emergency department: a retrospective study.Internal and emergency medicine · 2026Article
- Temporal association of constipation and diarrhoea with a subsequent diagnosis of colorectal cancer: a propensity score-matched case-control study using real-world primary care data.BMJ open gastroenterology · 2026Article
- Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment.International journal of clinical oncology · 2026Article
- The Role of Nursing Diagnoses in Enhancing Prognostic Accuracy in Home-Based Cancer Care: Insights From a Retrospective Cohort Study.Journal of clinical nursing · 2026Article
- Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study.World journal of urology · 2025Article
- Opioid-induced constipation in internal medicine: recognition and management pathways.Internal and emergency medicine · 2025Review
- Shouhui Tongbian Capsule ameliorates 5-fluorouracil induced constipation in mice by modulating gut microbiota and activating PI3K/AKT/AQP3 signaling pathway.Frontiers in microbiology · 2025Article
- Improving Diagnosis and Management of Opioid-Induced Constipation (OIC) in Clinical Practice: An Italian Expert Opinion.Journal of clinical medicine · 2024Article
- Gastro-Intestinal Symptoms in Palliative Care Patients.Current oncology (Toronto, Ont.) · 2024Review
- Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Management of pain in cancer patients - an update.Ecancermedicalscience · 2024Article
- Cancer management from a chronic gastrointestinal function perspective.Clinical medicine (London, England) · 2023Review
- Article
- Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Causal association between constipation and risk of colorectal cancer: a bidirectional two-sample Mendelian randomization study.Frontiers in oncology · 2023Article
- Adherence to coprescribing of laxatives with opioids and associated characteristics in general practices in the Netherlands.BMC primary care · 2022Observational
- Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementConstipation is one of the most frequent problems in cancer patients, and its etiology is multifactorial. It leads to decreased quality of life and impedes optimal pain treatment. Despite the high prevalence, constipation is frequently underdiagnosed mainly because of lack of validated diagnostic criteria or widely accepted definition of constipation in cancer patients. All cancer patients should be evaluated regularly for constipation, and concomitant causes and risk factors were assessed. Opioids are responsible for a much of the secondary constipation in cancer patients. The management of constipation in cancer patients should be multifaceted, addressing dietary and behavioral issues and optimizing pharmacological interventions. Prevention of opioid-induced constipation (OIC) is pivotal, as treatment is often unsatisfactory or inefficient. Dietary and behavioral interventions should be considered. Non-pharmacological measures include hydration and nutrition, ensuring privacy during defecation, using a commode or footstool, and the availability of a caregiver. Abdominal massage may be of value. Traditional laxatives are recommended in prevention but not in the treatment of OIC. Peripherally acting mu-opioid receptor antagonists (PAMORA) appear the first choice in the treatment and an alternative to laxatives in some recent clinical practice guidelines in preventing OIC. Naldemedine, naloxegol, and methylnaltrexone are supported by quality evidence for OIC management. Naloxone or naltrexone, taken orally in combined formulations with opioids, may be valuable in preventing or reducing OIC symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.